You are here

Home » Library » HCV Treatment in 2016: Genotypes 1, 2, and 3

HCV Treatment in 2016: Genotypes 1, 2, and 3

Publish date: October 12, 2016

Note: This is an archived resource. It is provided here for general reference, but users are advised to refer to other sources to confirm information. See full site Disclaimer.

AETC source: Southeast AETC

Objectives

  • List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
  • Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
  • Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Browse more

Language: English

Topic(s): Antiretroviral Therapy, Drug Interactions, OIs & Comorbid Conditions, Comorbidities, Coinfections, & Complications, Viral Hepatitis Coinfection

Resource type: Online and Self-Paced Learning

Add comment

Log in to post comments

Quick Survey

Select all that apply

We'd like your feedback

Check all that apply
Check all that apply
Include your email address if you would like a response
Include your email address if you would like a response